Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer

Summary

Objective: This study is to observe the safety and therapeutic effect of cryoablation combined with pd-1 antibody immunotherapy and anti-angiogenesis therapy in multiple primary lung cancer (MPLC) patients. Methods: In this study, 20 patients with MPLC who conform to the admission criteria are enrolled and began to receive treatment with Camrelizumab combined with Apatinib after cryoablation.

Timeline

Start

2019-12

Primary completion

2021-12

Completion

2022-12

Drugs

Indications